about
Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan.Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trialRegulation of blood-testis barrier (BTB) dynamics during spermatogenesis via the "Yin" and "Yang" effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2.B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cellsOSU-03012 interacts with lapatinib to kill brain cancer cellsEffect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysisMutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinicamTOR inhibition in management of advanced breast cancer.The role of mTOR signaling pathway in spinal cord injury.High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cellsThe Enigma of Rapamycin Dosage.The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.Outcomes of Pancreatic Islet Allotransplantation Using the Edmonton Protocol at the University of Chicago.mTOR Inhibition: From Aging to Autism and Beyond.Sustained PKCβII activity confers oncogenic properties in a phospholipase D- and mTOR-dependent manner.New function of type I IFN: induction of autophagy.mTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma.A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphomaEverolimus in colorectal cancer.Translation factors and ribosomal proteins control tumor onset and progression: how?Growing experience with mTOR inhibitors in pediatric solid organ transplantation.Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.Natural product and natural product derived drugs in clinical trials.The role of everolimus in liver transplantation.Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation.Effect of microRNA-101 on proliferation and apoptosis of human osteosarcoma cells by targeting mTOR.mTOR expression in human testicular seminoma.Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro.Safety profile and treatment response of everolimus in different solid tumors: an observational study.Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.Manipulation of autophagy in cancer cells: an innovative strategy to fight drug resistance.Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients.
P2860
Q33410223-EF7E4AA5-7CE2-463D-B268-C19805C6F123Q33410691-B59A4E24-DDBD-4ED5-9D71-50ADFA12E96CQ33863571-AADBA2BE-7DBF-4A05-AD61-382232356F30Q33946456-6163C8A1-D603-4090-9613-1CA7E01BBC52Q34300517-E74AD209-A205-4347-84DF-0364503B2D57Q34306540-D772513B-814E-4A6E-953A-D888C7ABAAD8Q34778631-584C8095-5CA6-4293-9CC8-FF219FE5916DQ35640506-648C03B0-E8C8-461A-BC47-B4C0692DB05CQ36228145-79D64682-7562-44EE-9D2A-8B8B32AACA34Q36304099-6DEF700C-F27A-4E03-91E8-28C0A5CCB985Q36544355-49825323-5F44-4779-9B7D-BA09926149DDQ36611732-FC5642A4-53C1-4999-A575-293E91320E76Q36664900-AC827A7B-91AF-4D17-B798-6635D56E3CB2Q36833480-DC569E4F-4966-4D02-99BC-6A38A2D99053Q37346582-83A52C56-6796-43D2-84E4-84D2486F9256Q37385781-8E60E818-AD67-433D-A29C-DF230DBB2A57Q37405255-5579C627-1EE3-4F91-A7BC-7599579E579AQ37585057-0100F5BE-386C-475A-968A-747381B50910Q37597433-B58A94D3-CE66-4882-8853-526F10A6352FQ37649637-A41C0C7A-B4AC-48E8-A852-52EB248CBA71Q38081233-9E68A401-CE6F-4DB5-A279-0D164D7E5BA7Q38104237-4B548941-65B7-48B3-BE21-49E74C0C5F43Q38134146-02D29564-7AA8-40CB-970F-EE6311E1BFDFQ38155511-E64EF20A-A108-4007-830B-2359BA855C49Q38247457-B6ED9127-6115-4AE2-B079-7C181B88332DQ38248591-1FA07488-7135-41BA-B11D-0039B16FC3A7Q38710557-14640222-C1CE-4424-B93B-CFDD6470F0BBQ38882776-DB98C0C9-3362-46E2-A1C4-B7F585729628Q38908325-BBB1E779-07D4-44D0-9DF8-A09F9943417BQ38931801-64975487-3791-466B-A0D9-6A0C5F6F9198Q38934078-F94BCEF8-A926-4436-B6BB-B49303A65BF9Q38939419-C8C92AFF-5F4E-4732-A7FE-F3BD9DA5627BQ38955246-6CDA109C-DE5E-40F8-8EBD-519C8972588DQ38957093-CFB15DC3-E914-415F-B4B6-AC1B85FCF144Q38962846-2AAC2C45-2E5A-46F7-A256-4D5F9A6E3041Q39141798-EA0D7BB0-E0BA-4878-B529-FB96B8CD306DQ39150764-0AFF3EDD-C43C-4CCF-8560-7A8CB8D9B0FAQ39182553-FEA9A29D-C790-413B-A0D1-A077BDD78233Q39407829-B7B49170-FEA7-4ED3-883A-C8B1DE5AD068Q41913207-DA954E0C-5A41-477E-87B7-C96A8553DC70
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting mTOR pathways in human malignancies.
@ast
Targeting mTOR pathways in human malignancies.
@en
Targeting mTOR pathways in human malignancies.
@nl
type
label
Targeting mTOR pathways in human malignancies.
@ast
Targeting mTOR pathways in human malignancies.
@en
Targeting mTOR pathways in human malignancies.
@nl
prefLabel
Targeting mTOR pathways in human malignancies.
@ast
Targeting mTOR pathways in human malignancies.
@en
Targeting mTOR pathways in human malignancies.
@nl
P1476
Targeting mTOR pathways in human malignancies.
@en
P2093
Angelica Fasolo
Cristiana Sessa
P304
P356
10.2174/138161212800626210
P577
2012-01-01T00:00:00Z